BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 20133085)

  • 21. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: a single-institute analysis of 742 patients.
    Cozzarini C; Fiorino C; Da Pozzo LF; Alongi F; Berardi G; Bolognesi A; Briganti A; Broggi S; Deli A; Guazzoni G; Perna L; Pasetti M; Salvadori G; Montorsi F; Rigatti P; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):191-9. PubMed ID: 21109361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.
    Peeters ST; Lebesque JV; Heemsbergen WD; van Putten WL; Slot A; Dielwart MF; Koper PC
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1151-61. PubMed ID: 16414208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.
    Arcangeli S; Strigari L; Soete G; De Meerleer G; Gomellini S; Fonteyne V; Storme G; Arcangeli G
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):39-45. PubMed ID: 18538488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity.
    Karlsdóttir A; Muren LP; Wentzel-Larsen T; Dahl O
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1478-86. PubMed ID: 18060703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect.
    Zapatero A; García-Vicente F; Modolell I; Alcántara P; Floriano A; Cruz-Conde A; Torres JJ; Pérez-Torrubia A
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1343-51. PubMed ID: 15275719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic conformal arc radiotherapy with rectum hollow-out technique for localized prostate cancer.
    Tomita N; Kodaira T; Tachibana H; Nakamura T; Tomoda T; Nakahara R; Inokuchi H; Hayashi N; Fuwa N
    Radiother Oncol; 2009 Mar; 90(3):346-52. PubMed ID: 18950880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation.
    Hepel JT; Tokita M; MacAusland SG; Evans SB; Hiatt JR; Price LL; DiPetrillo T; Wazer DE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1290-6. PubMed ID: 19395195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Acute toxicity in 50 patients with prostate cancer treated with conformal radiation therapy].
    Nasr E; Merhej S; Nehme Nasr D; Fares G
    J Med Liban; 2001; 49(6):325-8. PubMed ID: 12744634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT.
    Valdagni R; Rancati T; Fiorino C; Fellin G; Magli A; Baccolini M; Bianchi C; Cagna E; Greco C; Mauro FA; Monti AF; Munoz F; Stasi M; Franzone P; Vavassori V
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1065-73. PubMed ID: 18234449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
    Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
    Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects.
    Goldner G; Zimmermann F; Feldmann H; Glocker S; Wachter-Gerstner N; Geinitz H; Becker G; Pötzi R; Wambersie A; Bamberg M; Molls M; Wachter S; Pötter R
    Radiother Oncol; 2006 Jan; 78(1):36-40. PubMed ID: 16271410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer.
    Hanssen S; Norum J
    Anticancer Res; 2008; 28(5B):2865-8. PubMed ID: 19031926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.